REVIEW ARTICLE

Inappropriate treatments for patients with cognitive decline

A. Robles Bayón a,⁎, F. Gude Sampedro b

a Unidad de Neurología Cognitiva, Hospital La Rosaleda, Santiago de Compostela, Spain
b Unidad de Epidemiología Clínica, Hospital Clínico Universitario, Santiago de Compostela, Spain

Received 4 May 2012; accepted 28 May 2012
Available online 18 October 2012

KEYWORDS
Anticholinergics;
Anticholinesterases;
Benzodiazepines;
Memantine;
Opioids;
Polypharmacy

Abstract
Introduction: Some treatments are inappropriate for patients with cognitive decline. We analyse their use in 500 patients and present a literature review.
Development: Benzodiazepines produce dependence, and reduce attention, memory, and motor ability. They can cause disinhibition or aggressive behaviour, facilitate the appearance of delirium, and increase accident and mortality rates in people older than 60. In subjects over 65, low systolic blood pressure is associated with cognitive decline. Maintaining this figure between 130 and 140 mmHg (145 in patients older than 80) is recommended. Hypocholesterolaemia < 160 mg/dL is associated with increased morbidity and mortality, aggressiveness, and suicide; high-density lipoprotein (HDL)-cholesterol < 40 mg/dL is associated with memory loss and increased vascular and mortality risks. Old age is a predisposing factor for developing cognitive disorders or delirium when taking opioids. The risks of prescribing anticholinesterases and memantine to patients with non-Alzheimer dementia that is not associated with Parkinson disease, mild cognitive impairment, or psychiatric disorders probably outweigh the benefits. Anticholinergic drugs acting preferentially on the peripheral system can also induce cognitive side effects. Practitioners should be aware of steroid-induced dementia and steroid-induced psychosis, and know that risk of delirium increases with polypharmacy. Of 500 patients with cognitive impairment, 70.4% were on multiple medications and 42% were taking benzodiazepines. Both conditions were present in 74.3% of all suspected iatrogenic cases.
Conclusions: Polypharmacy should be avoided, if it is not essential, especially in elderly patients and those with cognitive impairment. Benzodiazepines, opioids and anticholinergics often elicit cognitive and behavioural disorders. Moreover, systolic blood pressure must be kept above 130 mmHg, total cholesterol levels over 160 mg/dL, and HDL-cholesterol over 40 mg/dL in this population.
© 2012 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

⁎ Please cite this article as: Robles Bayón A, Gude Sampedro F. Prescripciones inconvenientes en el tratamiento del paciente con deterioro cognitivo. Neurología. 2014;29:523–532.
⁎ Corresponding author.
E-mail address: alfredorobles@hospitalrosaleda.com (A. Robles Bayón).
Prescripciones inconvenientes en el tratamiento del paciente con deterioro cognitivo

Resumen

Introducción: Algunos fármacos resultan inconvenientes en pacientes con deterioro cognitivo. Se analiza su uso en 500 pacientes y se revisa la bibliografía.

Desarrollo: Las benzodiazepinas producen dependencia y reducen la atención, memoria y agilidad motora. Pueden inducir desinhibición o agresividad, facilitan los episodios confusionales e incrementan los accidentes y la mortalidad en mayores de 60 años. En mayores de 65, la presión sistólica baja se asocia a deterioro cognitivo. Es recomendable mantenerla en 130-140 mmHg (145 en ≥ 80 años). La colesterolemia < 160 mg/dl se asocia a mayor morbimortalidad, agresividad y suicidio, y el colesterol unido a las lipoproteínas de alta densidad (c-HDL) < 40 mg/dl empeora la memoria y aumenta el riesgo vascular y la mortalidad. La edad avanzada predispone para que los opioides produzcan alteración cognitiva y confusión. En demencias no Alzheimer y no asociadas a Parkinson, deterioro cognitivo ligero y enfermedades psiquiátricas, los efectos adversos de anticolinesterásicos y memantina probablemente superan al beneficio. La alteración cognitiva por anticolinérgicos de acción preferentemente periférica también es posible. Hay que conocer la demencia o psicosis por corticoides, y saber que la polifarmacía facilita el síndrome confusional. El 70,4% de 500 pacientes con disfunción cognitiva analizados recibía polifarmacía y el 42%, benzodiazepinas. Los que compartían ambas situaciones representaron el 74,3% de los casos en los que se sospechó iatrogenia.

Conclusiones: En personas con edad avanzada o deterioro cognitivo, es necesario evitar la polifarmacía innecesaria y tener presente que las benzodiazepinas, los opioides y los anticolinérgicos producen frecuentemente alteraciones cognitivas y conductuales. Además, deben evitarse la presión sistólica < 130 mmHg, el colesterol < 160 mg/dl y el colesterol HDL < 40 mg/dl.

© 2012 Sociedad Española de Neurologia. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Certain treatment plans, although apparently coherent, may be harmful to elderly patients or patients with cerebrovascular diseases, mild cognitive decline, or dementia. The present article reviews the disadvantages of treating certain patients with benzodiazepines (BZD), opioid analogues (OA), or anticholinergics (AC), as well as the risks of excessively strict treatment with hypolipaemic or antihypertensive drugs.

Procedure

Are BZD the best treatment option for anxiety, agitation, or insomnia?

In many clinical situations, BZDs and non-BZD hypnotics constitute the first-choice treatment for fighting anxiety, insomnia, and other related symptoms. Some active ingredients in this category are short-, medium-, or long-acting. Some of them have significant muscle relaxant or anticonvulsant properties, and different degrees of sedative or hypnotic efficacy (Table 1). Given this wide range of properties, target symptoms can be controlled with proper know-how. Short-term feedback from the patient and household members generally conveys satisfaction, which increases the doctor’s confidence in his or her prescribing habits. This may partially explain why BZD consumption has been increasing gradually. Data from the Spanish Agency for Medicines and Medical Devices’ report that 30.25 DDD were administered per 1000 inhabitants in 1992 (DDD = defined daily dose, or the average maintenance dose for a specific indication), whereas by 2006 it had risen to 62.14 DDD per 1000 inhabitants (an increase of 105%). Use of non-BZD sedative-hypnotics (zaleplon, zolpidem, zopiclone) rose from 1.64 DDD to 6.71 DDD per 1000 inhabitants (an increase of 309%).

We must be aware of the disadvantages of indiscriminate use of these agents. These drugs act on GABA receptors, inhibiting many cerebral functions. They decrease attention, certain memory functions, mental activation, and motor skills. From treatment onset, the rate of falls and fractures increases, and this trend rises more sharply with increasing age, dose, and drug half-life. Additionally, these drugs raise the incidence of accidents of all kinds (traffic, domestic, sport-related, and work-related). They can also generate paradoxical reactions, such as uninhibited or aggressive behaviours. On the other hand, BZDs and non-BZD sedative-hypnotics have an anterograde amnesic effect, aggravate memory deficits, and increase the risk of delirium episodes. Several experts suggest that adverse effects of sedative hypnotics exceed their benefits for people over 60, in addition to increasing mortality. In elderly people and those with cognitive decline, BZDs may be beneficial as treatment for agitated states. However, if the treatment length exceeds 3 weeks, patients may develop dependence (drug tolerance and symptoms of withdrawal syndrome), and some secondary effects may appear at an earlier time. Therefore, it is advisable to choose a different treatment when behavioural disorders are continuous or very frequent. Among alternative
Inappropriate treatments for patients with cognitive decline

Table 1 Principal benzodiazepines and non-benzodiazepine sedative-hypnotics

<table>
<thead>
<tr>
<th>Half-life ≤ 6 h&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Bentazepam</th>
<th>H</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Brotizolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Midazolam</td>
<td>AE, H</td>
</tr>
<tr>
<td></td>
<td>Triazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Zaleplon&lt;sup&gt;c&lt;/sup&gt;</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Zolpidem&lt;sup&gt;c&lt;/sup&gt;</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Zopiclone&lt;sup&gt;c&lt;/sup&gt;</td>
<td>H</td>
</tr>
<tr>
<td>Half-life 6–24 h&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Alprazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Bromazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Clotiazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Estazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Eszopiclone&lt;sup&gt;c&lt;/sup&gt;</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Loprazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Temazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Tetrazepam</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Lorazepam</td>
<td>AE</td>
</tr>
<tr>
<td></td>
<td>Lormetazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Oxazepam&lt;sup&gt;b&lt;/sup&gt;</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Pinazepam</td>
<td>H</td>
</tr>
<tr>
<td>Half-life &gt; 24 h&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Ciobazam</td>
<td>AE</td>
</tr>
<tr>
<td></td>
<td>Clonazepam</td>
<td>AE</td>
</tr>
<tr>
<td></td>
<td>Dipotassium clorazepate</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Clonazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Diazepam</td>
<td>AE, M</td>
</tr>
<tr>
<td></td>
<td>Flunitrazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Flurazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Halazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Ketazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Medazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Nitrazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Oxazolam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Prazepam</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td>Quazepam</td>
<td>H</td>
</tr>
</tbody>
</table>

AE: anticonvulsant and antiepileptic effect; H: significant hypnotic effect; M: significant muscle relaxant effect.

<sup>a</sup> Half-life of the drug or of its active metabolite, if applicable.

<sup>b</sup> Half-life in younger patients is usually just under 6 h, but it is slightly longer in elderly patients.

<sup>c</sup> Non-benzodiazepine sedative-hypnotic agent.

maintenance treatments, we should mention mood stabiliser anticonvulsants (such as pregabalin, whose indications include generalised anxiety disorder). Another class is constituted by antidepressants with an anxiolytic or sedative effect (especially when symptoms of depression are present): escitalopram, venlafaxine, duloxetine, trazodone, and mirtazapine. Additional alternative treatments include melatonin (for treating behavioural changes associated with circadian rhythm disturbances) and atypical neuroleptics previously administered to patients with this profile (for example, low doses of quetiapine, i.e. 12.5-200 mg/days in 1 or 2 daily doses).

Atypical neuroleptics are more effective in patients also experiencing delusional thinking and hallucinations. These neuroleptic agents must be selected correctly and long-term use must be avoided, since each drug is accompanied by predictable adverse effects and a potentially increased risk of mortality. Regardless of the treatment chosen, it is necessary to examine patients frequently in order to reduce doses or discontinue the drug as soon as possible. Adjuvant non-pharmacological treatments are also useful. The study began with a register of 500 patients aged 19 to 104 (mean age 75.2, median 77, all with cognitive dysfunction and 141 with symptoms of dementia) treated by a cognitive neurology department. Patients were asked whether they were being treated with BZDs or any non-BZD sedative-hypnotics at the time of the initial consult. Results are listed in Tables 2–5. A high percentage of patients (42%) were under treatment with one of these; this was more frequent in women and across all diagnostic groups (Table 4). For 74.2% of the patients receiving the treatment, the doctor estimated that the drugs were involved in the aetiology of cognitive symptoms, and that BZDs had an impact on 86.7% of all patients presenting totally or partially iatrogenic symptoms (Table 4).

Are strict controls for hypertension appropriate?

Hypertension in midlife increases the risk of developing dementia in later life, and treating the condition probably reduces that risk. However, the optimum ranges for systolic and diastolic blood pressure have changed over time, and they are still subject to debate. There is an association between low blood pressure, whether systolic or diastolic, and cognitive decline, especially in the elderly population. Attention and executive functions are more sensitive to changes in blood pressure than are other cognitive functions, such as language or memory functions. Patients with low cardiac ejection fraction show cognitive impairment and reduced motor skill due to cerebral hypoperfusion. Such deficiencies are more marked when patients also exhibit systolic hypotension.

According to a consensus document by experts from the American societies of Neurology, Geriatrics, Preventive Cardiology, Hypertension, and Nephrology, systolic blood pressure should not exceed 140 mmHg in people aged 65 to 79, and it should be maintained between 140 and 145 mmHg in people aged 80 or older. Most of the authors addressing this topic recommend that systolic blood pressure in this population should not be lower than 130 mmHg, except in patients with both heart failure and coronary artery disease.

Should cholesterol levels be kept as low as possible to decrease cardiovascular risk?

Prolonged high levels of cholesterol increase the risk of developing coronary artery disease and cerebral infarction. Therefore, lowering cholesterol is clearly beneficial in secondary prevention of adverse events associated with coronary artery disease. However, its efficacy in the primary prevention of cerebrovascular or cardiovascular...
accidents is less evident, especially for people over 75. Treatment must be selected carefully according to the risk level.28,39

On the other hand, low cholesterol levels (<160 mg/dl) are harmful to mental health and associated with higher morbidity and mortality rates.40,41 Low cholesterol is also associated with aggressive behaviour and higher incidence of suicide.42 Some studies have shown that reducing low-density lipoprotein cholesterol (LDL-C) to less than 120 mg/dl does not reduce cardiovascular risk.43 Furthermore, an excessive decrease in high-density lipoprotein cholesterol (HDL-C < 40 mg/dl) gives rise to memory decline44 and increases risk of mortality and also of stroke and coronary artery disease (especially in patients with diabetes).45,46 As a result, statin treatment in patients with dyslipidaemia must be adjusted to maintain cholesterol levels between 160 and 200 mg/dl, and niacin or fibrates must be included for patients with low HDL-C levels.39

**Should chronic pain therapy be aggressive?**

Chronic pain is common among the elderly and it reduces quality of life.47 In addition to attempting to target the cause, symptomatic treatment includes practical recommendations and medication, which may be administered orally or topically, or injected at the pain location.48 Pharmacological treatment comprises simple analgesics

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Age, sex, and diagnostic groups of the selected 500 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>W</td>
</tr>
<tr>
<td></td>
<td>318 (63.6)</td>
</tr>
<tr>
<td>Percentages in brackets.</td>
<td></td>
</tr>
<tr>
<td>DEGEN: clinical diagnosis of degenerative disease; IATR: an adverse drug effect is considered to have contributed to the cognitive symptoms; W: woman; OTHER_DX: any other diagnosis of cognitive impairment that is neither degenerative, vascular, nor iatrogenic in origin; S: 65 and older; VASC: clinical diagnosis of cerebrovascular disease.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Distribution of diagnoses including cases of combined aetiology (percentages given in brackets)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D-nonnD</td>
</tr>
<tr>
<td>I-nonO</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>O-nonO</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>I+O</td>
<td>0 (0)</td>
</tr>
<tr>
<td>NonnO</td>
<td>49 (9.8)</td>
</tr>
<tr>
<td>D: clinical diagnosis of degenerative disease; I: an adverse drug effect is considered to have contributed to the cognitive symptoms; O: any other diagnosis of cognitive impairment that is neither degenerative, vascular, nor iatrogenic in origin; V: clinical diagnosis of cerebrovascular disease.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Distribution of the 500 patients according to types of treatment observed (data shown as percentages)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
</tr>
<tr>
<td>BZDs</td>
<td>42.0</td>
</tr>
<tr>
<td>OAs</td>
<td>6.0</td>
</tr>
<tr>
<td>PP</td>
<td>70.4</td>
</tr>
<tr>
<td>DEGEN: clinical diagnosis of degenerative disease; IATR: an adverse drug effect is considered to have contributed to the cognitive symptoms; J: younger than 65; W: woman; OTHER_DX: any other diagnosis of cognitive impairment that is neither degenerative, vascular, nor iatrogenic in origin; PP: polypharmacy; S: 65 and older; M: man; VASC: clinical diagnosis of cerebrovascular disease.</td>
<td></td>
</tr>
<tr>
<td>Chi-square test:</td>
<td></td>
</tr>
<tr>
<td>a Not significant.</td>
<td></td>
</tr>
<tr>
<td>b P &lt; .001 (S vs J, and M vs W).</td>
<td></td>
</tr>
<tr>
<td>c P &lt; .05.</td>
<td></td>
</tr>
<tr>
<td>d P &lt; .001 (expressed percentage vs percentage of patients with the same diagnosis but not receiving that treatment).</td>
<td></td>
</tr>
<tr>
<td>e P &lt; .05 (M vs W).</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Combinations of observed treatment regimens in the 500 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Polypharmacy</td>
</tr>
<tr>
<td></td>
<td>OAs yes</td>
</tr>
<tr>
<td>BZDs yes</td>
<td>21 (4.2%)</td>
</tr>
<tr>
<td>BZDs no</td>
<td>8 (1.6%)</td>
</tr>
</tbody>
</table>
(paracetamol or metamizole), anti-inflammatory agents, and opiates analgesics (strong OAs, such as morphine, hydromorphone, buprenorphine, methadone, fentanyl, oxy-
codone, meperidine, and tapentadol, and weak OAs, such as tramadol, codeine, dihydrocodeine and dextro-
propoxyphene). There are also adjuvant drugs including coanalgesics and coadjuvants. Coanalgesics lessen certain
types of pain and include certain anticonvulsants (pre-
gabapin, gabapentin, lamotrigine, carbamazepine, oxcar-
bazepine, clonazepam, topiramate), certain muscle relax-
ant drugs (baclofen, tizanidine), selected antidepressants
(especially amitriptyline and other tricyclic antidepress-
pants), and selective norepinephrine and serotonin reuptake
inhibitors ( duloxetine, venlafaxine; mirtazapine). On the
other hand, coadjuvant drugs indirectly lessen pain or
its repercussions (anxiolytics and non-analgesic antide-
prescents when anxiety or depression are involved, muscle
relaxants for contractures, antibiotics for infections, lax-
avitives for constipation, etc.). The previously mentioned
disadvantages of BZD treatment must be considered when
adjuvant drugs are prescribed. Additionally, we should
take into account that tricyclic antidepressants have an AC
effect, which may worsen cognitive state in elderly patients
or those whose condition progresses with cholinergic defi-
ciences. BZDs may also lead to orthostatic hypotension
or severe complications in patients with arrhythmia or
atroventricular block. Furthermore, combinations such as
tramadol and antidepressant agents may lead to serotonin
syndrome.49

Correct use of analgesic drugs (including OAs) in patients
with long-term pain may improve functional status and
social engagement in the elderly.50 Easy-to-use OAs with
an increasingly better tolerability appeared on the market
in the past 25 years. Some examples are hydromorphone
(sustained-release oral morphine), oral tramadol, transder-
mal fentanyl patches, and tapentadol. Since tapentadol acts
as both an OA and a norepinephrine reuptake inhibitor, it is
effective with fewer secondary effects. Changes in the phar-
macopoeia resulted in an 128.4% increase in OA use in Spain
between 1992 and 2006 (from 0.32 to 4.43 DDD per 1000
inhabitants).51

In elderly individuals, OAs can alter cognition and perception,
even in cases of renal failure or dehydration.52 These drugs
can also be dangerous in patients with an underlying pulmonary condition and in those whose medica-
tion causes respiratory depression.53 Due to their potential
adverse effects and ability to cause dependence, they are
restricted to cases of acute or chronic pain that does not
respond to other types of analgesic treatment.

Several review articles on iatrogenic delirium show that
OA use increases the likelihood of developing the disease
by a factor of 2 or 3 among patients at risk.54 Risk factors
include age over 65, cognitive decline, severe illness, hip
fracture in the acute phase, poor nutrition, dehydration,
alcohol or drug abuse, visual or hearing impairment, sleep
deprivation, and low level of activity.55 Precipitating factors
include intense pain, infections, alcohol or drug withdrawal,
stress, various medical procedures and electrolyte distur-
bances. Furthermore, Solomon et al.54 noticed that elderly
people on OA treatment had an increased risk of cardio-
vascular accidents, fractures, and mortality compared to
elderly NSAID users.

Therefore, OAs must be avoided when alternative drugs
offer reasonably effective pain treatment, especially in
elderly patients and those with decline in cognitive function.
Considering that pain itself can trigger delirium, opioids may
be used when available alternatives are ineffective. In such
cases, we should be mindful that low to moderate doses
(equivalent to less than 40 mg/day of morphine) have a more
beneficial impact on quality of life than high doses.55 In fact,
many elderly people require down-adjustment of dosage due
to comorbidities and drug-drug interactions.56 Doctors must
examine patients frequently to identify any adverse effects
as soon as possible.

In the group of 500 patients analysed in the present study,
30 patients were treated with opioids (6%), and most were
women (Table 4). It is believed that drug therapy was par-
tially responsible for cognitive symptoms in 23 patients, all
of whom were polymedicated (12.7% of the cases included
iatrogenic effects) (Tables 4–6).

Should cholinesterase-inhibitor treatment be
tested in patients with mild cognitive impairment
associated with Alzheimer disease or with
non-Alzheimer dementia?

Patients who meet clinical criteria for Alzheimer disease
(AD) must start treatment with cholinesterase inhibitors
(ChEI) unless specific circumstances contraindicate these
drugs. Memantine is prescribed in intermediate stages
of dementia. Clinical diagnosis of typical AD focuses on
verifying that the patient has hippocampal amnesia (dif-
culty in registering new information). Complementary
tests will show a pathophysiological marker of AD (decreased
amyloid-β42 levels and increased phosphorylated tau lev-
els in cerebrospinal fluid, tempo-parietal hypoactivity in
functional neuroimaging scans, or hippocampal atrophy in
structural neuroimaging scans). At present, and perhaps as
long as there are no available drugs which modify the clinical
course of the disease, current healthcare practice usually
focuses on testing the reported episodic memory alterations
and using magnetic resonance imaging (MRI) techniques
to reveal hippocampal thinning and confirm absence of other
cerebral lesions which may justify all the symptoms.

AD is not the only cause of hippocampal amnesia. The
hippocampus and its limbic circuits can be altered, there-
fore causing related amnesia symptoms in patients affected
by trauma or surgery, or patients with anoxia, ischaemia,
herpesviral encephalitis, tumours, hypothyroidism, and
autoimmune diseases (for example, neurological lupus or
autoimmune limbic encephalitis).56–59 Therefore, AD
diagnosis cannot be based solely on neuropsychological
examination. On the other hand, hippocampal atrophy
shown by MRI does not necessarily point to underlying
AD. Alterations may be caused by hippocampal sclerosis
of another aetiology (vascular, anoxic, or due to idiopathic
or non-specific tauopathies),50 old age,50 Cushing syndrome
and other diseases associated with increased glucocorticoid
activity (recurrent major depression, some cases of pro-
longed post-traumatic stress disorder),60–62 chronic bilateral
vestibular loss,64 prolonged treatment with valproic acid,65
prior history of perinatal hypoxia-ischaemia,66 or they may
be due to unknown causes. Subcortical ischaemic vascular dementia may also result in hippocampal atrophy.

Trials of ChEIs in patients with mild cognitive impairment have shown that this treatment does not delay onset of dementia and is associated with more adverse effects than placebo. For example, ChEIs are associated with a four-fold increase in the risk of syncope. In patients with pure vascular dementia, donepezil and galantamine improve cognition, but not all examined aspects of functional status. Rivastigmine also lacks efficacy, in addition to being associated with an increase in vascular adverse effects and mortality. In 2011, the British Association for Psychopharmacology advised against ChEIs for treating frontotemporal dementia. These drugs have only been officially indicated or mentioned in guidelines for the treatment of AD, dementia associated with Parkinson’s disease, and Lewy body dementia. Further investigations are needed to prescribe ChEIs for other diseases such as Down syndrome, progressive supranuclear palsy, Huntington disease, multiple sclerosis, epilepsy, acute confusional syndrome, traumatic brain injury, sleep disorders, schizophrenia and bipolar disorder.

Before prescribing drugs off-label, doctors must consider the patient’s risk of adverse effects. Cholinergic stimulation of the cerebral cortex, striate body, and brainstem, and increased peripheral cholinergic activity may cause a number of symptoms, whether cognitive-behavioural (confusion, agitation, anxiety), extrapyramidal (tremor), sleep-related (drowsiness, insomnia, nightmares), cardiorespiratory (bradycardia, syncope, exacerbation of symptoms associated with asthma or chronic obstructive pulmonary disease), and digestive (nausea, vomiting, diarrhoea, abdominal pain, anorexia, weight loss). It may also cause weakness, muscle cramps, or urinary incontinence. Elderly people and those under treatment with conventional or atypical antipsychotics are more likely to develop severe adverse effects.

In many pathological states of the nervous system, excitotoxicity promotes functional and structural damage. This is why experiments have shown that memantine has neuroprotective effects in patients with cerebral ischaemia, intraparenchymal cerebral haemorrhage, HIV-associated dementia, head trauma, carbamate insecticide poisoning, glaucoma, motor neuron diseases, Huntington disease, Parkinson’s disease, and AD. At present, AD is the only disease with sufficient clinical and therapeutic evidence to support use of this treatment. In patients with mild AD, trials of memantine showed no significantly beneficial effects. In patients with Parkinson’s disease and dementia, or Lewy body dementia, overall clinical impression improved substantially whereas cognition and functional performance did not. In contrast, memantine showed a positive impact on cognition in patients with mild to moderate vascular dementia, although this effect did not significantly improve the overall clinical impression or functional performance. A pilot study in patients with Huntington disease showed that memantine was associated with less pronounced choreic movements, but not with improved cognition, behaviour, or functional performance. In a phase II trial, memantine did not improve neuropsychological performance in patients with HIV-associated cognitive decline. In another trial including patients with amyotrophic lateral sclerosis, memantine treatment showed no efficacy. A glutamatergic dysfunction is present in schizophrenia and in mood, anxiety, and obsessive-compulsive disorders. This being the case, treatment with memantine has been studied (and sometimes prescribed off-label) in patients with depression, bipolar disorder, schizophrenia, pervasive developmental disorder, obsessive-compulsive disorder, bulimia, and substance addictions. Some findings show treatment to be potentially beneficial, for example, in alcoholic patients or patients with catatonic schizophrenia. However, the quality of evidence is insufficient to draw conclusions since there are few large studies and results are frequently contradictory.

Before prescribing a drug off-label, we must bear in mind that while memantine is generally well-tolerated, it can cause such adverse effects as headache and constipation, and it may slightly increase the risk of seizures.

Miscellaneous

It seems logical that ACs acting mainly on the brain, such as antiparkinsonian drugs (orphenadrine, biperiden, trihexyphenidyl, benzatropine, procyclidine, tetrabenazine), are harmful to cognition in patients with diseases that cause cholinergic deficiencies (AD, Lewy body dementia, some cases of vascular dementia, etc.). ACs may also alter cognition or behaviour in elderly people because this group presents cholinergic deficiencies resulting from physiological decreases in cellularity in cholinergic nuclei and in the density of muscarinic receptors. A more obscure fact is that certain ACs with a more selective peripheral action can penetrate the blood-brain barrier and cause this kind of effect. Even more surprisingly, this may occur when drugs are administered topically or by inhalation. Such is the case for drugs to treat overactive bladder, which exhibit certain differences. They range from oxybutynin, which penetrates the blood-brain barrier more easily and has a lower tolerability than the rest, to trospium chloride, which barely enters the central nervous system. AC eye drops, sublingual atropine to reduce sialorrhea in terminal patients and those with Parkinson’s disease, and scopolamine to reduce terminal bronchial secretions or to prevent motion sickness are all unusual treatments with potential central or peripheral AC effects. There are case reports of delirium triggered by inhaled AC bronchodilators, but such cases are very rare since absorption into the bloodstream is minimal. AC action has been identified in drugs pertaining to other pharmacological groups (OAs, tricyclic antidepressants, antihistamines, antipsychotics, BZDs, some antibiotics and immunosuppressants, captopril, cypsoxephtadine, chlortalidone, codeine, corticosteroids, furosemide, digoxin, diltiazem, isosorbide dinitrate, dipyridamole, disopyramide, hydrochlorothiazide, metoclopramide, rifampicin, paroxetine, quinidine, ranitidine, theophylline, triamterene, warfarin). These drugs can exert an adjuvant AC effect when used simultaneously or with more powerful ACs.

It should be mentioned that treatment with steroids (even budesonide) can occasionally, and for short periods of time, cause dementia (steroid dementia) and/or psychotic symptoms (steroid psychosis).
In times, the cognitive or behavioural adverse effects are not caused by improper drug selection, but rather by excessively large doses (a common occurrence with elderly patients) or prolonged use (which results in higher risk in the case of sedative and/or addictive drugs).

According to the WHO, polypharmacy is the use of more than 3 drugs per patient at one time. This is necessary on some occasions in patients with multiple diseases. In other cases, the patient’s list of drugs contains a drug that is not indicated, not effective, whose action overlaps or is incompatible with that of another drug, or that is contraindicated in that patient. In polypharmacy patients, interactions are sometimes unpredictable due to the great variety of combined chemical formulas. Interactions are more frequent in elderly people, who do not usually metabolise and eliminate drugs in an optimal way. More specifically, polypharmacy promotes development of confusional syndrome; at times, the drug provoking the disorder may directly or indirectly prolong a confusional state.97

The 500 patients examined here were taking between 0 and 19 drugs (mean 5.5). Polypharmacy patients accounted for 70.4% of the total. Polypharmacy was more frequent in patients 65 or older with no diagnosis of degenerative disease (Table 4). Both BZDs and OAs were more frequently associated with polypharmacy (*P* < .001 in both cases; Table 5). However, in the case of OAs, only the frequency of polypharmacy was significantly associated with drug-related cognitive symptoms (*P* < .05) (Table 6).

### Conclusions

In daily practice we must be aware that treatments, dosage and duration must be carefully determined for elderly patients who present cognitive impairment, cerebrovascular disease, severe diseases, or diseases affecting systemic metabolism or the integrity of the blood-brain barrier. Polypharmacy should also be avoided when certain drugs are not necessary or suitable. BZDs and other sedative drugs, OAs, and any drug with AC effects are especially likely to cause acute or chronic cognitive-behavioural disturbances in vulnerable patients. Additionally, systolic blood pressure should not be allowed to drop below 130 mmHg in patients with atheromatosis and a loss of elasticity in the arteries leading to the brain, and cholesterol levels should not be reduced excessively (total cholesterol < 160 mg/dL, HDL-C < 40 mg/dL).

In the sample of 500 patients with altered cognitive functions, large numbers of patients were treated with BZDs (42%, mostly women) or on a polypharmacy regimen (70.4%, more frequent in patients 65 and older). Polypharmacy patients taking BZDs accounted for 74.3% of the cases in which an iatrogenic factor was suspected in the aetiology of cognitive symptoms.

### Conflicts of interest

The authors have no conflicts of interest to declare.

### References


Inappropriate treatments for patients with cognitive decline


63. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925–35.


77. Anónimo. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. Prescrire Int. 2011;20:95.


